Flúter auricular posiblemente relacionado con pazopanib: descripción de un caso

Ana Puebla Villaescusa; Estrella Díaz Gómez; Ángel Luis Salcedo Mingoarranz; Sebastián Ramírez Cruz; Francisco José Hidalgo Correas; Benito García Díaz

doi:10.7399/fh.10887

Flúter auricular posiblemente relacionado con pazopanib: descripción de un caso

Ana Puebla Villaescusa, Estrella Díaz Gómez, Ángel Luis Salcedo Mingoarranz, Sebastián Ramírez Cruz, Francisco José Hidalgo Correas, Benito García Díaz

Resumen

Palabras clave

Texto completo:

PDF

Referencias

Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis. 2010;13(1):1-14. DOI: 10.1007/s10456-009-9160-6

Abdallah A-O, Vallurupalli S, Kunthur A. Pazopanib- and bevacizumab- induced reversible heart failure in a patient with metastatic renal cell carcinoma: A case report. J Oncol Pharm Practice. 2016;22(3):561-5.

Boudou-Rouquette P, Tlemsani C, Blanchet B, Huillard O, Jouinot A, Arrondeau J, et al. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. Expert Opin Drug Metab Toxicol. 2016;12(12):1433-44.

Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-8. DOI: 10.1200/JCO.2009.23.9764

Agencia Española de Medicamentos y Productos Sanitarios. CIMA (Centro de Información de Medicamentos). Ficha técnica de pazopanib [Internet]. España [Consultado Agosto 2017]. Disponible en: https://www.aemps.gob.es/cima/pdfs/es/ft/10628004/FT_10628004.pdf

Van Marcke C, Ledoux B, Petit B, Seront E. Rapid and fatal acute heart failure induced by pazopanib. BMJ Case Rep. [revista en Internet] 2015 [Consultado febrero 2017]. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567752/pdf/bcr-2015- 211522.pdf

Granada J, Uribe W, Chyou P-H, Maassen K, Vierkant R, Smith PN, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36(7):2242-6.

Kloth JSL, Pagani A, Verboom MC, Malovini A, Napolitano C, Kruit WHJ, et al. Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors. Br J Cancer. 2015;112(6):1011-6.

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma [página Web]. ClinicalTrials.gov Identifier: NCT00334282. 2006 [feb 2016; feb 2017]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT00334282

Pinkhas D, Ho T, Smith S. Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. Cardio-Oncol [revista en Internet] 2017[2017];3(5). Disponible en: https://link.springer.com/content/pdf/10.1186%2Fs40959-017-0024- 8.pdf

Karch FE, Lasagna L. Toward the operational identification of adverse drug reactions. Clin Pharmacol Ther. 1977;21(3):247-54.

EudraVigilance: European database of suspected side-effect reports [Base de datos en Internet] [Agosto 2017]. Disponible en: http://www.adrreports.eu/en/index.html

DOI: http://dx.doi.org/10.7399%2Ffh.10887